Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Penumbra Inc Stock Research

PEN

236.12USD-2.51(-1.05%)Delayedas of 03 Oct 2023, 12:04 pm
Watchlist

Market Summary

USD236.12-2.51
Delayedas of 03 Oct 2023, 12:04 pm
-1.05%

PEN Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

PEN Stock Price

PEN RSI Chart

PEN Valuation

Market Cap

9.1B

Price/Earnings (Trailing)

313.94

Price/Sales (Trailing)

9.75

EV/EBITDA

140.44

Price/Free Cashflow

17.9K

PEN Price/Sales (Trailing)

PEN Profitability

Operating Margin

63.17%

EBT Margin

1.99%

Return on Equity

0.63%

Return on Assets

0.46%

Free Cashflow Yield

0.01%

PEN Fundamentals

PEN Revenue

Revenue (TTM)

937.8M

Revenue Y/Y

25.51%

Revenue Q/Q

8.33%

PEN Earnings

Earnings (TTM)

29.1M

Earnings Y/Y

614.24%

Earnings Q/Q

121.44%

Price Action

52 Week Range

144.76348.67
(Low)(High)

Last 7 days

-3.4%

Last 30 days

-9.6%

Last 90 days

-29.6%

Trailing 12 Months

25.9%

PEN Financial Health

Current Ratio

5.37

PEN Investor Care

Shares Dilution (1Y)

1.47%

Diluted EPS (TTM)

0.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for PEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-11
Elsesser Adam
acquired
74,911
7.75
9,666
ceo and president
2023-09-11
Elsesser Adam
sold
-2,887,820
298
-9,666
ceo and president
2023-09-08
Kassing Don W.
sold
-128,165
288
-444
-
2023-09-01
Roberts Johanna
sold
-159,067
265
-600
evp, gen. counsel & secretary
2023-09-01
Grewal Harpreet
sold
-90,650
266
-340
-
2023-09-01
O'Rourke Bridget
sold
-26,662
266
-100
-
2023-09-01
Sarna Surbhi
sold
-22,662
266
-85.00
-
2023-08-14
Roberts Johanna
sold
-149,910
249
-600
evp, gen. counsel & secretary
2023-08-11
Elsesser Adam
acquired
74,911
7.75
9,666
ceo and president
2023-08-11
Elsesser Adam
sold
-2,389,570
247
-9,666
ceo and president

1–10 of 50

Which funds bought or sold PEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
sold off
-100
-981,825
-
-%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
2,684
14,128
-%
2023-09-20
BARCLAYS PLC
added
208
6,489,000
8,799,000
0.01%
2023-08-23
WOLVERINE TRADING, LLC
new
-
222,602
222,602
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
unchanged
-
274,554
1,445,050
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.12
2,616,290
15,169,600
0.02%
2023-08-21
OSAIC HOLDINGS, INC.
added
19.92
823,066
2,536,880
-%
2023-08-21
VisionPoint Advisory Group, LLC
new
-
344
344
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
2.54
1,822,000
8,678,000
0.08%
2023-08-17
Coppell Advisory Solutions LLC
new
-
47,029
47,029
0.01%

1–10 of 45

Latest Funds Activity

Are funds buying PEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PEN
No. of Funds

Schedule 13G FIlings of Penumbra

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital research global investors
6.1%
2,321,719
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.13%
3,467,792
SC 13G/A
Jan 23, 2023
blackrock inc.
11.6%
4,422,738
SC 13G/A
Feb 11, 2022
capital research global investors
7.4%
2,770,020
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 04, 2022
wellington management group llp
0.00%
14
SC 13G/A
Feb 03, 2022
blackrock inc.
9.0%
3,356,220
SC 13G/A
Feb 16, 2021
capital research global investors
8.9%
3,248,192
SC 13G
Feb 10, 2021
vanguard group inc
8.42%
3,057,710
SC 13G/A

Recent SEC filings of Penumbra

View All Filings
Date Filed Form Type Document
Oct 02, 2023
144
Notice of Insider Sale Intent
Oct 02, 2023
144
Notice of Insider Sale Intent
Sep 13, 2023
4
Insider Trading
Sep 12, 2023
4
Insider Trading
Sep 08, 2023
144
Notice of Insider Sale Intent
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 01, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Penumbra)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.0B
19.5B
-3.73% 35.20%
38.38
5.34
10.36% 30.30%
103.6B
6.7B
-4.97% 57.37%
72.72
15.55
11.75% -0.66%
76.4B
13.4B
-1.51% 36.35%
83.74
5.7
8.69% 3.17%
71.3B
19.0B
-7.43% 16.56%
44.09
3.79
0.46% -5.24%
42.1B
5.7B
-9.43% -16.28%
30.27
7.43
5.64% -4.53%
MID-CAP
9.1B
937.8M
-9.65% 25.86%
313.94
9.75
16.30% 250.21%
7.2B
616.6M
-11.74% -29.40%
29.51
11.67
69.52% 343.68%
5.0B
1.1B
-8.56% -16.75%
23.67
4.54
12.63% 50.85%
2.8B
452.1M
-10.08% -26.48%
-28.35
6.22
24.99% 24.09%
1.4B
790.3M
-21.04% -54.04%
-6.37
1.81
3.21% -1604.53%
SMALL-CAP
1.5B
421.8M
-22.58% 43.94%
-9.18
3.63
44.49% -2.43%
945.1M
780.7M
-5.83% -7.35%
-26.25
1.21
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
589.9M
162.9M
-22.80% -66.22%
-11.16
3.62
42.67% 12.82%

Penumbra News

MarketBeat
Exchange Traded Concepts LLC Sells 925 Shares of Penumbra, Inc ....
MarketBeat,
6 hours ago
Nasdaq

Returns for PEN

Cumulative Returns on PEN

18.1%


7-Year Cumulative Returns

11.1%


5-Year Cumulative Returns

8.5%


3-Year Cumulative Returns

Risks for PEN

What is the probability of a big loss on PEN?

100%


Probability that Penumbra stock will be more than 20% underwater in next one year

58.9%


Probability that Penumbra stock will be more than 30% underwater in next one year.

18.9%


Probability that Penumbra stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Penumbra was unfortunately bought at previous high price.

Drawdowns

Financials for Penumbra

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue6.0%937,791884,636847,133829,928806,367782,281747,590710,477671,436592,287560,412538,777527,203556,295547,405522,935495,239470,676444,938420,196392,301
Gross Profit5.9%591,687558,861535,207522,227506,812491,463475,382444,248415,259361,503338,175341,990347,065376,063371,964352,548331,562309,886292,533277,548257,313
Operating Expenses2.7%555,523540,725529,125561,035542,273516,473482,883413,437413,387387,592377,117368,608340,549339,097324,456308,950321,789303,631293,385281,213239,446
  S&GA Expenses2.8%474,716461,896449,718447,588433,412409,433378,331341,434323,195292,413287,068285,153278,284286,095272,733259,221245,866232,977226,385216,679206,707
  R&D Expenses3.2%83,79181,153-81,92475,80973,381-70,06494,316100,965-94,12565,87253,521-49,72945,08839,81936,16533,69932,739
EBITDA-100.0%-42,81828,213-20,557-18,402-9,4105,90644,05416,251-11,402-25,127-14,01117,39346,73958,23953,234-----
EBITDA Margin-100.0%-0.05*0.03*-0.02*-0.02*-0.01*0.01*0.06*0.02*-0.02*-0.04*-0.03*0.03*0.08*0.11*0.10*-----
Earnings Before Taxes117.3%38,35117,6483,892-44,190-39,443-28,073-10,50229,9412,428-24,805-38,018-25,7586,93637,48050,13545,73512,8649,0131,608-1,83519,312
EBT Margin-100.0%-0.02*0.00*-0.05*-0.05*-0.04*-0.01*0.04*0.00*-0.04*-0.07*-0.05*0.01*0.07*0.09*0.09*-----
Net Income349.4%29,1286,481-2,002-30,512-19,391-6,4735,28433,56515,900-5,291-15,702-9,66110,63739,18548,45845,42815,01511,8086,6019,02528,193
Net Income Margin-100.0%-0.01*0.00*-0.04*-0.02*-0.01*0.01*0.05*0.02*-0.01*-0.03*-0.02*0.02*0.07*0.09*0.09*-----
Free Cashflow100.0%--56,253-74,959-90,096-40,191-2,790-11,678-152-38,503-60,306-57,998-55,379-33,543-6,9774,54312,251-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Assets2.7%1,4331,3951,3711,3221,3281,3021,244973841823810780664666614585569515501499490
  Current Assets5.3%828786756724718690681668635618590576454463451435423411398392388
    Cash Equivalents20.6%11495.0070.0055.0058.0068.0059.0066.0056.0070.0080.0013472.0073.0011277.0096.0068.0048.0060.0051.00
  Inventory4.3%35934433432029627426425824522019218316615314013312211611098.0095.00
  Net PPE1.1%66.0065.0065.0064.0063.0060.0059.0057.0050.0048.0065.0062.0059.0052.0046.0038.0035.0035.0034.0034.0032.00
  Goodwill0.0%1661661661651661661661598.008.008.008.008.008.007.008.008.008.008.008.008.00
Liabilities-1.3%36637137234835834229028919018519115717618014713113213592.0074.0075.00
  Current Liabilities-1.5%14414614513814613012311611210610878.0088.0091.0086.0070.0069.0066.0065.0050.0050.00
Shareholder's Equity4.1%1,0671,024999974970959954685650638620623488486467454437422409425415
  Retained Earnings36.1%71.0052.0044.0040.0042.0046.0046.0071.0052.0041.0037.0046.0058.0058.0048.0036.0020.009.002.0021.008.00
  Additional Paid-In Capital2.2%1,001979963947938919911621603598585581436431423419420415408404404
Shares Outstanding0.4%38.0038.0038.0038.0038.0038.0038.0037.0036.0036.0036.0035.0035.0035.0035.0035.0035.0034.0034.0034.0034.00
Minority Interest---------6.20-4.62-3.71-2.69-1.63-0.82-0.28-0.390.00-0.070.00-0.13--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations149.1%19.00-38.02-55.66-66.27-16.9119.0010.0017.00-23.31-41.69-33.24-26.39-0.7923.0027.0029.0018.0016.0029.0020.0021.00
  Share Based Compensation9.8%45.0041.0037.0069.0067.0068.0066.0032.0030.0026.0026.0023.0023.0022.0021.0021.0020.0019.0018.0018.0018.00
Cashflow From Investing-54.9%22.0050.0055.0045.00-14.80-9.11-21.73-30.62-30.21-111-104-137-73.96-34.53-12.7141.006.0034.00-0.38-26.40-29.58
Cashflow From Financing-2.8%15.0016.0012.009.007.001.001.000.001.00137135132132-11.60-8.96-5.29-4.90-4.78-9.81-10.54-10.19

PEN Income Statement

2023-06-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 261,499$ 208,344$ 502,897$ 412,239
Cost of revenue94,63874,309184,964150,786
Gross profit166,861134,035317,933261,453
Operating expenses:    
Research and development21,53719,55941,52340,123
Sales, general and administrative127,435114,615250,513225,515
Total operating expenses148,972134,174292,036265,638
Income (loss) from operations17,889(139)25,897(4,185)
Interest income (expense), net839(72)1,393(119)
Other income (expense), net808(956)898(1,967)
Income (loss) before income taxes19,536(1,167)28,188(6,271)
Provision for (benefit from) income taxes5762,520666(2,663)
Net income (loss)$ 18,960$ (3,687)$ 27,522$ (3,608)
Net income (loss) per share:    
Basic (in dollars per share)$ 0.49$ (0.10)$ 0.72$ (0.10)
Diluted (in dollars per share)$ 0.48$ (0.10)$ 0.70$ (0.10)
Weighted average shares outstanding:    
Basic (in shares)38,320,99937,767,51938,254,04237,707,156
Diluted (in shares)39,201,15537,767,51939,151,41237,707,156

PEN Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 114,167$ 69,858
Marketable investments106,896118,172
Accounts receivable, net of allowance for credit losses of $4,775 and $862 at June 30, 2023 and December 31, 2022, respectively208,965203,384
Inventories358,770334,006
Prepaid expenses and other current assets39,07830,279
Total current assets827,876755,699
Property and equipment, net65,95865,015
Operating lease right-of-use assets187,494192,636
Finance lease right-of-use assets31,75133,323
Intangible assets, net76,11681,161
Goodwill166,166166,046
Deferred taxes66,67164,213
Other non-current assets10,50012,793
Total assets1,432,5321,370,886
Current liabilities:  
Accounts payable25,81926,679
Accrued liabilities105,606106,300
Current operating lease liabilities10,71510,033
Current finance lease liabilities1,9841,920
Total current liabilities144,124144,932
Non-current operating lease liabilities194,655198,955
Non-current finance lease liabilities23,92224,865
Other non-current liabilities3,2883,276
Total liabilities365,989372,028
Commitments and contingencies
Stockholders’ equity:  
Common stock3838
Additional paid-in capital1,000,658963,040
Accumulated other comprehensive loss(5,579)(8,124)
Retained earnings71,42643,904
Total Penumbra, Inc. stockholders’ equity1,066,543998,858
Total liabilities and stockholders’ equity$ 1,432,532$ 1,370,886
Adam Elsesser
3800
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.